The cancer risks and spectra appear to differ between BRCA1 and BRCA2 carriers; specifically, the risk for ovarian cancer in BRCA1 carriers is higher than BRCA2 carriers2,7,17, and the risks for pancreatic and prostate cancers in BRCA2 carriers may be higher than BRCA1 carriers7,9–11,18. This evidence concerns the gene BRCA2 and prostate carcinoma.